Henan Lingrui Pharmaceutical Co (SHSE:600285) 5-Year EBITDA Growth Rate : 14.90% (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Henan Lingrui Pharmaceutical Co 5-Year EBITDA Growth Rate?

Henan Lingrui Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.39.

During the past 12 months, Henan Lingrui Pharmaceutical Co's average EBITDA Per Share Growth Rate was 31.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 19.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 14.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Henan Lingrui Pharmaceutical Co was 37.00% per year. The lowest was -15.90% per year. And the median was 13.40% per year.

Competitive Comparison of Henan Lingrui Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Lingrui Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Henan Lingrui Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Lingrui Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Henan Lingrui Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.

Henan Lingrui Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Henan Lingrui Pharmaceutical Co (SHSE:600285) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Henan Lingrui Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Henan Lingrui Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Henan Lingrui Pharmaceutical Co (SHSE:600285) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Henan Lingrui Pharmaceutical Co Ltd (SHSE:600285) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

No. 59 Jiefang Chengguan Road, Xinxian, Xinyang, Henan, CHN, 465550

Website

http://www.lingrui.com

Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.

Executives

Wu Xi Zhen	Director
Li Jin	Supervisors
Ye Qiang	senior management
Chen Yan	Directors, senior managers
Wu Hui Bin	senior management
Yu Peng	Director
Zhao Zhi Jun	Director
Li Lei	senior management
Feng Guo Xin	Directors, senior managers
Pan Zi Run	Director
Xiong Wei Zheng	Director
Tang Wei	Supervisors
Cheng Jian Jun	Director
Zhang Jun Bing	Director
Xia Hui	senior management

Henan Lingrui Pharmaceutical Co (SHSE:600285) Headlines

No Headlines